Shares of Becton Dickinson & Co. BDX advanced 1.34% to $201.78 Friday, on what proved to be an all-around favorable trading ...

Becton Dickinson & Co. closed 20.98% short of its 52-week high of $251.99, which the company reached on February 3rd.

Barclays lowered the firm’s price target on Becton Dickinson (BDX) to $261 from $279 and keeps an Overweight rating on the shares. The firm ...

Becton, Dickinson & Co (Symbol: BDX) presently has an above average rank, in the top 50% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further ...

In its fourth quarter 2024 investor letter, Generation Global Equity Strategy emphasized stocks such as Becton, Dickinson and Company (NYSE:BDX). Becton, Dickinson and Company (NYSE:BDX ...

Becton Dickinson (BDX) announced the first patient treated in an investigational device exemption clinical trial intended to advance BD’s efforts to achieve premarket approval from the FDA for ...

Becton Dickinson is in preliminary talks to divest its $21 billion Life Sciences unit, exploring multiple options with major medtech players and diagnostics firms.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...

After four years with the Jets, offensive lineman Mekhi Becton was viewed as a major disappointment: The 11th overall pick in the 2020 NFL draft, Becton missed more games than he played and never ...